Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Blood Adv. 2024 May 14;8(9):2130-2132. doi: 10.1182/bloodadvances.2023011433.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Male
  • Receptors, Chimeric Antigen
  • Vidarabine* / analogs & derivatives
  • Vidarabine* / therapeutic use